MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
7.82
+0.11
+1.43%
Opening 09:38 09/10 EDT
OPEN
7.80
PREV CLOSE
7.71
HIGH
7.99
LOW
7.79
VOLUME
127.36K
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
5.25
MARKET CAP
1.43B
P/E (TTM)
-69.5730
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and MannKind (MNKD)
TipRanks · 4h ago
Oppenheimer Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
TipRanks · 5h ago
Analysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (XERS) and Pharvaris (PHVS)
TipRanks · 6h ago
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and Disc Medicine (IRON)
TipRanks · 6h ago
Xeris Biopharma price target raised to $16 from $12 at Leerink
TipRanks · 7h ago
Xeris Highlights XP-8121 Strategy and Growth Roadmap
TipRanks · 1d ago
Xeris Biopharma hosts webinar on XP-8121 development program
TipRanks · 1d ago
Xeris Biopharma To Host XP‑8121 Program Overview Detailing Phase 3 Study And Commercial Opportunity; Topline Results Expected In Late 2028; FDA Approval And Launch Anticipated In 2030
Benzinga · 1d ago
More
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.